
Nicholas A. Mcfall
Examiner (ID: 9647, Phone: (571)270-5769 , Office: P/3644 )
| Most Active Art Unit | 3644 |
| Art Unit(s) | 3644 |
| Total Applications | 685 |
| Issued Applications | 577 |
| Pending Applications | 48 |
| Abandoned Applications | 75 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 13593371
[patent_doc_number] => 20180348234
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-12-06
[patent_title] => PEPTIDE COMBINATIONS FOR USE IN THE DIAGNOSIS OF SCHIZOPHRENIA
[patent_app_type] => utility
[patent_app_number] => 15/744532
[patent_app_country] => US
[patent_app_date] => 2016-07-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5829
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 60
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15744532
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/744532 | Peptide combinations for use in the diagnosis of schizophrenia | Jul 13, 2016 | Issued |
Array
(
[id] => 15083521
[patent_doc_number] => 20190336571
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-11-07
[patent_title] => NEUROTOXIN FOR USE IN THE TREATMENT OF PERSONALITY DISORDERS
[patent_app_type] => utility
[patent_app_number] => 15/746889
[patent_app_country] => US
[patent_app_date] => 2016-07-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3848
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 46
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15746889
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/746889 | NEUROTOXIN FOR USE IN THE TREATMENT OF PERSONALITY DISORDERS | Jul 12, 2016 | Abandoned |
Array
(
[id] => 15618841
[patent_doc_number] => 20200079825
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-03-12
[patent_title] => RARE PHOSPHORYLATED HIGH MOLECULAR WEIGHT (HMW) TAU SPECIES THAT ARE INVOLVED IN NEURONAL UPTAKE AND PROPAGATION AND APPLICATIONS THEREOF
[patent_app_type] => utility
[patent_app_number] => 15/743787
[patent_app_country] => US
[patent_app_date] => 2016-07-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 57647
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15743787
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/743787 | RARE PHOSPHORYLATED HIGH MOLECULAR WEIGHT (HMW) TAU SPECIES THAT ARE INVOLVED IN NEURONAL UPTAKE AND PROPAGATION AND APPLICATIONS THEREOF | Jul 12, 2016 | Abandoned |
Array
(
[id] => 13887797
[patent_doc_number] => 10196439
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-02-05
[patent_title] => Antibodies specific for hyperphosphorylated tau and methods of use thereof
[patent_app_type] => utility
[patent_app_number] => 15/207836
[patent_app_country] => US
[patent_app_date] => 2016-07-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 51
[patent_figures_cnt] => 51
[patent_no_of_words] => 36730
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 155
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15207836
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/207836 | Antibodies specific for hyperphosphorylated tau and methods of use thereof | Jul 11, 2016 | Issued |
Array
(
[id] => 14551277
[patent_doc_number] => 10344081
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-07-09
[patent_title] => Tau-binding antibodies
[patent_app_type] => utility
[patent_app_number] => 15/742070
[patent_app_country] => US
[patent_app_date] => 2016-07-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 8
[patent_no_of_words] => 25989
[patent_no_of_claims] => 38
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 64
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15742070
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/742070 | Tau-binding antibodies | Jul 4, 2016 | Issued |
Array
(
[id] => 14294453
[patent_doc_number] => 10287343
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-05-14
[patent_title] => Tau-binding antibodies
[patent_app_type] => utility
[patent_app_number] => 15/742087
[patent_app_country] => US
[patent_app_date] => 2016-07-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 23
[patent_figures_cnt] => 17
[patent_no_of_words] => 25769
[patent_no_of_claims] => 32
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 63
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15742087
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/742087 | Tau-binding antibodies | Jul 4, 2016 | Issued |
Array
(
[id] => 11649153
[patent_doc_number] => 20170145055
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-05-25
[patent_title] => 'PEPTIDE INHIBITORS OF CASPASE 2 ACTIVATION'
[patent_app_type] => utility
[patent_app_number] => 15/194144
[patent_app_country] => US
[patent_app_date] => 2016-06-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 25
[patent_figures_cnt] => 25
[patent_no_of_words] => 14071
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15194144
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/194144 | PEPTIDE INHIBITORS OF CASPASE 2 ACTIVATION | Jun 26, 2016 | Abandoned |
Array
(
[id] => 12837517
[patent_doc_number] => 20180171012
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-06-21
[patent_title] => Anti-Human Transferrin Receptor Antibody Permeating Blood-Brain Barrier
[patent_app_type] => utility
[patent_app_number] => 15/739200
[patent_app_country] => US
[patent_app_date] => 2016-06-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 76593
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -61
[patent_words_short_claim] => 99
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15739200
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/739200 | Anti-human transferrin receptor antibody permeating blood-brain barrier | Jun 23, 2016 | Issued |
Array
(
[id] => 13675155
[patent_doc_number] => 20160376311
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-12-29
[patent_title] => PEPTOIDS AND METHODS FOR TREATING ALZHEIMER'S DISEASE
[patent_app_type] => utility
[patent_app_number] => 15/191925
[patent_app_country] => US
[patent_app_date] => 2016-06-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8283
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 8
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15191925
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/191925 | Peptoids and methods for treating Alzheimer's disease | Jun 23, 2016 | Issued |
Array
(
[id] => 11456102
[patent_doc_number] => 20170050008
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-02-23
[patent_title] => 'METHODS FOR IMPROVING DRUG EFFICACY'
[patent_app_type] => utility
[patent_app_number] => 15/191603
[patent_app_country] => US
[patent_app_date] => 2016-06-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 16359
[patent_no_of_claims] => 35
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15191603
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/191603 | Methods for improving drug efficacy | Jun 23, 2016 | Issued |
Array
(
[id] => 17192143
[patent_doc_number] => 11160875
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-11-02
[patent_title] => Therapeutic nanofiber hydrogels for local treatment of brain-related diseases
[patent_app_type] => utility
[patent_app_number] => 15/736818
[patent_app_country] => US
[patent_app_date] => 2016-06-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 19
[patent_figures_cnt] => 61
[patent_no_of_words] => 13228
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 60
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15736818
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/736818 | Therapeutic nanofiber hydrogels for local treatment of brain-related diseases | Jun 15, 2016 | Issued |
Array
(
[id] => 12808816
[patent_doc_number] => 20180161442
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-06-14
[patent_title] => METHODS FOR THE TREATMENT OF LEPTOMENINGEAL CARCINOMATOSIS
[patent_app_type] => utility
[patent_app_number] => 15/737188
[patent_app_country] => US
[patent_app_date] => 2016-06-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9527
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15737188
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/737188 | Methods for the treatment of leptomeningeal carcinomatosis | Jun 14, 2016 | Issued |
Array
(
[id] => 11335630
[patent_doc_number] => 20160361385
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-12-15
[patent_title] => 'METHOD FOR TREATING ALZHEIMER\'S DISEASE USING SUPERIOR STABILITY TUBULIN CONSRUCTS'
[patent_app_type] => utility
[patent_app_number] => 15/180764
[patent_app_country] => US
[patent_app_date] => 2016-06-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 5
[patent_no_of_words] => 6466
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15180764
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/180764 | METHOD FOR TREATING ALZHEIMER'S DISEASE USING SUPERIOR STABILITY TUBULIN CONSRUCTS | Jun 12, 2016 | Abandoned |
Array
(
[id] => 13106823
[patent_doc_number] => 10072044
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2018-09-11
[patent_title] => Modified kisspeptin peptides and uses thereof
[patent_app_type] => utility
[patent_app_number] => 15/180031
[patent_app_country] => US
[patent_app_date] => 2016-06-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 16
[patent_no_of_words] => 8805
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 43
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15180031
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/180031 | Modified kisspeptin peptides and uses thereof | Jun 11, 2016 | Issued |
Array
(
[id] => 12728815
[patent_doc_number] => 20180134772
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-05-17
[patent_title] => Anti-CGRP Antibody Formulation
[patent_app_type] => utility
[patent_app_number] => 15/578263
[patent_app_country] => US
[patent_app_date] => 2016-06-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8222
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -49
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15578263
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/578263 | Anti-CGRP antibody formulation | Jun 7, 2016 | Issued |
Array
(
[id] => 11074272
[patent_doc_number] => 20160271236
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-09-22
[patent_title] => 'RECOMBINANT T-CELL RECEPTOR LIGAND FOR THE TREATMENT OF COGNITIVE AND NEUROPSYCHIATRIC IMPAIRMENT INDUCED BY SUBSTANCE ADDICTION'
[patent_app_type] => utility
[patent_app_number] => 15/174372
[patent_app_country] => US
[patent_app_date] => 2016-06-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 15
[patent_figures_cnt] => 15
[patent_no_of_words] => 25208
[patent_no_of_claims] => 34
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15174372
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/174372 | RECOMBINANT T-CELL RECEPTOR LIGAND FOR THE TREATMENT OF COGNITIVE AND NEUROPSYCHIATRIC IMPAIRMENT INDUCED BY SUBSTANCE ADDICTION | Jun 5, 2016 | Abandoned |
Array
(
[id] => 13604059
[patent_doc_number] => 20180353578
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-12-13
[patent_title] => METHODS AND COMPOSITIONS FOR TREATING AGING-ASSOCIATED CONDITIONS
[patent_app_type] => utility
[patent_app_number] => 15/736583
[patent_app_country] => US
[patent_app_date] => 2016-06-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20863
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 35
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15736583
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/736583 | Methods and compositions for treating aging-associated conditions | Jun 5, 2016 | Issued |
Array
(
[id] => 13675235
[patent_doc_number] => 20160376351
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-12-29
[patent_title] => ANTI-TAU ANTIBODIES AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 15/171143
[patent_app_country] => US
[patent_app_date] => 2016-06-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 54598
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -45
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15171143
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/171143 | Anti-Tau antibodies and methods of use | Jun 1, 2016 | Issued |
Array
(
[id] => 11066230
[patent_doc_number] => 20160263194
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-09-15
[patent_title] => 'TREATMENTS FOR MIGRAINE AND RELATED DISORDERS'
[patent_app_type] => utility
[patent_app_number] => 15/171327
[patent_app_country] => US
[patent_app_date] => 2016-06-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 15
[patent_figures_cnt] => 15
[patent_no_of_words] => 28707
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15171327
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/171327 | Treatments for migraine and related disorders | Jun 1, 2016 | Issued |
Array
(
[id] => 11335658
[patent_doc_number] => 20160361413
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-12-15
[patent_title] => 'COMPOUNDS FOR USE IN THE TREATMENT OF ALZHEIMER\'S DISEASE'
[patent_app_type] => utility
[patent_app_number] => 15/150958
[patent_app_country] => US
[patent_app_date] => 2016-05-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 13
[patent_figures_cnt] => 13
[patent_no_of_words] => 11025
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15150958
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/150958 | COMPOUNDS FOR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE | May 9, 2016 | Abandoned |